Kazia Therapeutics

Company snapshot

Kazia Therapeutics Limited (NASDAQ: KZIA) is a clinical-stage oncology company focused on high-need cancers of the central nervous system and select aggressive solid tumors. Founded in 2016, the company is dedicated to advancing transformative therapies by harnessing next-generation science, disciplined development, and a commitment to clinical impact. Our mission is to redefine cancer treatment b

• 13 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 13 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Kazia Therapeutics. Not investment advice.

• deal Jun 2, 2026

  Kazia Therapeutics Appoints James Levine as Chief Financial Officer

• Peer + 0 momentum

  BEONE MEDICINES AUS

  TA overlap score 40

• Peer + 0 momentum

  GT Biopharma

  TA overlap score 21.6

Recent activity

Latest pipeline, patent, and corporate events for Kazia Therapeutics.

1. Jun 8, 2026 Clinical update

   Part A: Dose Escalation of Cantrixil — Phase 1

2. Jun 5, 2026 Clinical update

   PAXALISIB — Phase 2

3. Jun 5, 2026 Clinical update

   Paxalisib — Phase 2

4. Jun 5, 2026 Clinical update

   idronoxil — Phase 1

5. Jun 5, 2026 Clinical update

   GDC-0084 — Phase 1

View all clinical trial activity →

• What is Kazia Therapeutics?

  Kazia Therapeutics is a pharma organization headquartered in Barangaroo, AU. It trades on NYSE under ticker KZIA. Primary therapeutic focus areas include CDK Gene Mutation, Solid Tumor, Adult, Brain and Central Nervous System Tumors, Brain Metastases, Unspecified Adult Solid Tumo

• Is Kazia Therapeutics publicly traded?

  Yes. Kazia Therapeutics is listed with ticker KZIA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Kazia Therapeutics develop or market?

  We link 9 drug profile(s) where Kazia Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/kazia-therapeutics-ltd#company-drugs.

• What are the latest developments for Kazia Therapeutics?

  In the last 12 months our linked public records show 13 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Kazia Therapeutics focus on?

  Kazia Therapeutics focuses on CDK Gene Mutation, Solid Tumor, Adult, Brain and Central Nervous System Tumors based on our analysis of their pipeline programs and drug development activities.